We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

VATS Lobectomy for Clinical Stage IB or II Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00425022
Recruitment Status : Unknown
Verified January 2007 by National Cancer Center, Korea.
Recruitment status was:  Recruiting
First Posted : January 22, 2007
Last Update Posted : January 30, 2007
Information provided by:

Study Description
Brief Summary:
To examine the feasibility of VATS lobectomy for clinical stage IB or II non-small cell lung cancer. Success is defined as VATS lobectomy without conversion. If success rate over 90%, VATS lobectomy is considered as feasible procedures for clinical stage IB or II non-small cell lung cancer

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Thoracic Surgery, Video-Assisted Procedure: thoracoscopy Phase 2

Detailed Description:

Video-assisted or minimally invasive surgery has become the standard approach for many abdominal surgical operations such as cholecystectomy and fundoplication. With respect to the thorax, video-assisted thoracoscopic surgery(VATS) is the accepted technique for biopsy of the lung and pleura and surgical treatment of pneumothorax.Thoracoscopic, also termed video-assisted thoracoscopic lobectomy has become accepted as a safe and effective procedure to treat early-stage non-small cell lung cancer (NSCLC). Several pilot series of thoracoscopic lobectomy in stage I lung cancer patients have been reported, demonstrating low complication rates and effective short-term and long-term oncologic results. With increasing experience, the indications for thoracoscopic lobectomy have been expanded. Single and Multi-institutional studies have demonstrated that thoracoscopic lobectomy is not only a safe and feasible technique, but is also associated with decreased morbidity, including shorter length of hospitalization and chest tube duration, decreased postoperative pain, improved preservation of pulmonary function, reduced inflammatory response as measured by lower postoperative cytokine levels, and shorter recovery time, as compared with conventional thoracotomy. The advantages of thoracoscopic lobectomy have been demonstrated in patients with clinical stage I NSCLC, and this strategy has been found to be particularly useful for specific subsets of patients such as the elderly and those patients with poor performance status.

The purpose of this study is to know whether VATS lobectomy for clinical stage IB or II non-small cell lung cancer is possible.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility of VATS(Video-Assisted Thoracoscopic Surgery) Lobectomy for Clinical Stage IB or II Non-Small Cell Lung Cancer
Study Start Date : January 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. To examine the feasibility of VATS lobectomy for clinical stage IB or II non-small cell lung cancer.
  2. Success is defined as VATS lobectomy without conversion.
  3. If success rate over 90%, VATS lobectomy is considered as feasible procedures for clinical stage IB or II non-small cell lung cancer

Secondary Outcome Measures :
  1. To evaluate the number of dissected lymph nodes and the rate of contamination during lymph node dissection according to the lymph node stations under VATS
  2. To estimate the reccurrence rate (locoregional and distant metastasis)
  3. To estimate the overall survival
  4. To evaluate the intraoperative(surgical duration, estimated blood loss) and postoperative variables(mortality, morbidity, chest tube drainage duration, wound pain, hospital stay)
  5. To evaluate inflammatory mediators after VATS

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologic or cytologic diagnosis of non-small cell lung cancer.
  2. Clinical stage IB or II, according to the American Joint Committee on Cancer (AJCC).
  3. Tumor ≤ 6 cm in size amenable to surgical resection.
  4. Including clinical IB or II NSCLC after neoadjuvant therapy
  5. Performance status of 0-1 on ECOG scale.
  6. At least 18 years old.
  7. Patient compliance that allows adequate follow-up.
  8. Medical fitness of patients adequate for radical NSCLC surgery.
  9. Adequate organ function including the following:Adequate hematologic function: WBC count ³ 4,000/uL, absolute neutrophil count (ANC) ³ 1,500/uL, platelet count ³ 100,000/uL, and hemoglobin ³ 10 gm/dL.Adequate hepatic function: bilirubin £ 1.5 x UNL, ALT or AST £ 2.5 x UNL.Adequate renal function: creatinine £ 1.5mg/dL.
  10. Signed informed consent from patient or legal representative.
  11. Patients with reproductive potential must use an approved contraceptive method during and for 3 months after the study. Females with childbearing potential must have a negative urine hCG test within 7 days prior to study enrollment.

Exclusion Criteria:

  1. Metastatic disease in workup
  2. Any T3, T4 lesion or N2, N3 lesion
  3. Concurrent administration of other tumor therapy, including radiotherapy, immunotherapy except chemotherapy.
  4. Active uncontrolled infection.
  5. Serious concomitant disorders that would compromise the safety of patient or compromise the patient’s ability to tolerate therapy.
  6. Significant neurological or mental disorder.
  7. Previous history of malignancy in any organ
  8. Pregnant or nursing.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00425022

Contact: Hyun-Sung Lee, MD, PhD +82-31-920-1648 thoracic@ncc.re.kr

Korea, Republic of
National Cancer Center Recruiting
Goyang, Gyeonggi, Korea, Republic of, 411-769
Contact: Hyun-Sung Lee, MD, PhD    +82-31-920-1648    thoracic@ncc.re.kr   
Sub-Investigator: Jae Ill Zo, MD,PhD         
Sub-Investigator: Jong Mog Lee, MD         
Sub-Investigator: Moon Soo Kim, MD         
Sub-Investigator: Bin Hwangbo, MD         
Sub-Investigator: Hee Seok Lee, MD         
Sub-Investigator: Hyae Young Kim, MD, PhD         
Sub-Investigator: Kun Young Lim, MD         
Sub-Investigator: Soo-Hyun Lee, MD         
Sub-Investigator: Geon Kook Lee, MD, PhD         
Sub-Investigator: Moon Woo Seong, MD         
Sub-Investigator: Byoung-ho Nam, PhD         
Sponsors and Collaborators
National Cancer Center, Korea
Principal Investigator: Hyun-Sung Lee, MD, PhD National Cancer Center, Korea
More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00425022     History of Changes
Other Study ID Numbers: NCCCTS-06-223
First Posted: January 22, 2007    Key Record Dates
Last Update Posted: January 30, 2007
Last Verified: January 2007

Keywords provided by National Cancer Center, Korea:
lung cancer
video-assisted thoracic surgery

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms